JDS Business Summary

Jourdeness Group Limited (4190.TW), identified by the market variant JDS, operates a vertically integrated beauty and biotechnology business model that spans R&D, manufacturing, and a global service network. The company generates revenue through high-margin professional spa services, the retail sale of proprietary skincare brands like Jenduoste, and tourism-related income from its "Jourdeness Castle" biotech park, which serves as a major retail and brand experience hub. Its operations are divided into four primary segments: SPA Chain Stores (directly operated and franchised), Cosmetics Manufacturing (ODM/OEM), Medical Beauty Clinics, and the Sightseeing Factory division. Within the regional beauty landscape, JDS competes directly with Natural Beauty (NB), Arwin, and Proya Cosmetics. JDS maintains a dominant market position by controlling its entire value chain, allowing for rapid product iteration and a seamless "service-to-product" ecosystem that differentiates it from pure-play manufacturers or retail-only competitors. The company is led by its founder, Chen Cheng-Hsiung, who serves as Chairman and Chief Strategy Officer, leveraging over three decades of experience to guide the group’s expansion into medical beauty and tourism. The executive leadership is spearheaded by CEO and General Manager Chia-Chi Chen, who has been instrumental in the group’s digital transformation and international scaling since her appointment in 2017. The C-suite is further supported by CFO Cheng Hsiao-Hui, who oversees financial strategy and accounting, and Chief Administration Officer Yu-Chien Chen. Notable recent additions to the management team include Chief Information Security Officer Teng Ting-Sheng, reflecting a strategic focus on data security and digital infrastructure. The board is characterized by high stability and significant insider alignment, with the founding family and key executives maintaining a controlling interest of approximately 57%, ensuring a long-term commitment to the group’s diversified biotechnology roadmap.